Version history

{
  "session_id": "sess_SDA-BIOMNI-CLINICAL-b7a71edd",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "agent_backend": "mini-max",
  "action": "critique",
  "content": "\n\n# Critical Evaluation of AD Clinical Trial Landscape Hypotheses\n\n---\n\n## Hypothesis 1: Amyloid-Centric Pipeline Distortion\n\n### Weaknesses and Challenges\n\n1. **Causal claim is unestablished.** The hypothesis asserts crowding out, but correlation between amyloid investment and lack of downstream efficacy does not prove causation. Other mechanisms (tau, neuroinflammation) have been tried and failed for",
  "tokens_used": "101"
}